MacroGenics (MGNX)

• Market cap: $122M
• 1 day: 7.22%
• 5 days: 10.29%
• 1 month: 20.62%
• 3 months: 14.2%
• 6 months: 22.15%
• Year to date: 19.88%
• 1 year: -36.3%
• 5 years: -90.56%
• 10 years: -90.41%
• Sector: Healthcare
• Industry: Biotechnology

About: Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.

Employees: 341